Optical imaging using a blue light-sensitive optical dye illuminates a flat lesion of the bladder (right) not apparent under white light. GE Healthcare plans to begin distribution of the dye, Hexvix, in Europe in the second half of 2006. The company expects FDA approval by year's end, at which time it could begin distributing the agent under an existing arrangement with PhotoCure, the Norwegian company that developed Hexvix.
Optical imaging using a blue light-sensitive optical dye illuminates a flat lesion of the bladder (right) not apparent under white light. GE Healthcare plans to begin distribution of the dye, Hexvix, in Europe in the second half of 2006. The company expects FDA approval by year's end, at which time it could begin distributing the agent under an existing arrangement with PhotoCure, the Norwegian company that developed Hexvix.
If approved by the FDA, Hexvix would be the first optical imaging agent for bladder cancer available to the U.S. market. Worldwide, bladder cancer ranks fourth in men and eighth in women in terms of mortality due to cancer.
After being introduced into the bladder, Hexvix combines selectively with cancer growing in the superficial tissue. The dye causes the cancer to fluoresce and appear more clearly during blue-light cystoscopy. Multicenter research supporting European approval of Hexvix demonstrates that fluorescence cystoscopy identifies about 30% more patients with the aggressive form of superficial bladder cancer compared with white-light cystoscopy. Its use is recommended by the European Association of Urology in guidelines released in September 2005.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.